Close Menu

Gilead Sciences

Early trials give conflicting results on remdesivir to treat COVID-19, though a large trial suggests it shortens disease length, Nature News reports.

In PLOS this week: genomic analysis of multidrug-resistant Mycobacterium tuberculosis strains from Colombia, inflammatory response signatures in cancer, and more.

Second Genome will use its Microbiome Analytics platform to identify novel biomarkers linked to clinical responses to Gilead's investigational medicines.

The international firm is one of several pharmaceutical companies emphasizing new single-cell technologies to improve existing drugs and find new ones.

Slow Adoption

Reuters reports that slow adoption of CAR-T therapies might be tied to their high prices.

The agreement is part of Biocartis' long term plans to expand its presence in the oncology field by building a menu of tests for immunotherapies.

Miles to Go

Technology Review maps out where new gene therapies for cancer patients are available, noticing an urban-rural divide.

The lead investigators said that Foundation Medicine's NGS test will enable the beginning of targeted treatment within seven days of diagnosis. 

Lasker Honorees

The Albert and Mary Lasker Foundation has announced this year's recipients of its prizes honoring basic and clinical research.

NEW YORK (GenomeWeb) – The Yale School of Medicine today said that it and Gilead Sciences have extended a research collaboration to identify the genetic and molecular bases of cancer.

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.